<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:xhtml="http://www.w3.org/1999/xhtml">

  <url>
    <loc>https://www.regaffairshub.com/</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/"/>
    <lastmod>2026-04-05</lastmod>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/tools</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/tools"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/tools?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/tools?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/tools?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/tools"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/contact</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/contact"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/contact?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/contact?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/contact?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/contact"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/tools/classify</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/tools/classify"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/tools/classify?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/tools/classify?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/tools/classify?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/tools/classify"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/tools/tracker</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/tools/tracker"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/tools/tracker?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/tools/tracker?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/tools/tracker?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/tools/tracker"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.9</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/eu-mdr-classification-guide</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/eu-mdr-classification-guide"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/eu-mdr-classification-guide?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/eu-mdr-classification-guide?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/eu-mdr-classification-guide?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/eu-mdr-classification-guide"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/ectd-submission-structure</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/ectd-submission-structure"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/ectd-submission-structure?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/ectd-submission-structure?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/ectd-submission-structure?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/ectd-submission-structure"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/fda-vs-eu-mdr-comparison"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/ivdr-transition-guide</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/ivdr-transition-guide"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/ivdr-transition-guide?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/ivdr-transition-guide?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/ivdr-transition-guide?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/ivdr-transition-guide"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/clinical-evaluation-report-guide</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/clinical-evaluation-report-guide"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/clinical-evaluation-report-guide?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/clinical-evaluation-report-guide?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/clinical-evaluation-report-guide?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/clinical-evaluation-report-guide"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/iso-13485-lean-qms-guide"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/eu-mdr-2026-deadlines"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide</loc>
    <xhtml:link rel="alternate" hreflang="en" href="https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide"/>
    <xhtml:link rel="alternate" hreflang="es" href="https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide?lang=es"/>
    <xhtml:link rel="alternate" hreflang="ca" href="https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide?lang=ca"/>
    <xhtml:link rel="alternate" hreflang="fr" href="https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide?lang=fr"/>
    <xhtml:link rel="alternate" hreflang="x-default" href="https://www.regaffairshub.com/blog/biosensor-regulatory-pathway-guide"/>
    <lastmod>2026-04-05</lastmod>
    <priority>0.8</priority>
  </url>
</urlset>
